| Original language | English |
|---|---|
| Pages (from-to) | 657-658 |
| Number of pages | 2 |
| Journal | Annals of Allergy, Asthma and Immunology |
| Volume | 129 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 2022 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Annals of Allergy, Asthma and Immunology, Vol. 129, No. 6, 12.2022, p. 657-658.
Research output: Journal article (peer-reviewed) › Editorial
TY - JOUR
T1 - Avoiding avoidance in milk and egg allergy
AU - Wong, Dennis
AU - Eiwegger, Thomas
AU - Upton, Julia E M
N1 - Funding Information: Disclosures: Dr Eiwegger reports having recent or current positions as a local principal investigator for company-sponsored trials by DBV Therapeutics and Greer Stallergens and as a subinvestigator for Regeneron and ALK Abello; is a coinvestigator or scientific lead in 3 investigator-initiated oral immunotherapy trials supported by the SickKids Food Allergy and Anaphylaxis Program; serves as an associate editor for Allergy; reports receiving unconditional or kind contributions from Macro Array Diagnostics and ALK Abello (him/his laboratory); holds advisory board roles for ALK Abello, Aimmune, VAMED, and Nutricia/Danone; and reports receiving lecture fees from ALK Abello, Nutricia/Danone, Thermo Fisher, Aimmune, and Novartis. Dr Upton reports receiving research support or grants from Novartis, Regeneron, ALK Abello, DBV Therapeutics, CIHR, and SickKids Food Allergy and Anaphylaxis Program; and fees from Pfizer, ALK Abello, Bausch Health, Kaleo, AstraZeneca, and Food Allergy Canada, all outside the submitted work. Dr Wong has no conflicts of interest to disclose. Funding Information: Funding: The authors have no funding sources to report. Disclosures: Dr Eiwegger reports having recent or current positions as a local principal investigator for company-sponsored trials by DBV Therapeutics and Greer Stallergens and as a subinvestigator for Regeneron and ALK Abello; is a coinvestigator or scientific lead in 3 investigator-initiated oral immunotherapy trials supported by the SickKids Food Allergy and Anaphylaxis Program; serves as an associate editor for Allergy; reports receiving unconditional or kind contributions from Macro Array Diagnostics and ALK Abello (him/his laboratory); holds advisory board roles for ALK Abello, Aimmune, VAMED, and Nutricia/Danone; and reports receiving lecture fees from ALK Abello, Nutricia/Danone, Thermo Fisher, Aimmune, and Novartis. Dr Upton reports receiving research support or grants from Novartis, Regeneron, ALK Abello, DBV Therapeutics, CIHR, and SickKids Food Allergy and Anaphylaxis Program; and fees from Pfizer, ALK Abello, Bausch Health, Kaleo, AstraZeneca, and Food Allergy Canada, all outside the submitted work. Dr Wong has no conflicts of interest to disclose.
PY - 2022/12
Y1 - 2022/12
UR - http://www.scopus.com/inward/record.url?scp=85142132335&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2022.09.019
DO - 10.1016/j.anai.2022.09.019
M3 - Editorial
C2 - 36464391
SN - 1081-1206
VL - 129
SP - 657
EP - 658
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 6
ER -